drugset
drugset / Trial / NCT07476001

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

NCT07476001 ↗

Phase 2 Recruiting 12 enrolled H. Lee Moffitt Cancer Center and Research Institute
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5 months.

Timeline

Start
2026-03-03
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Cypionate Small molecule 400 mg Intramuscular
Subject VIPIVOTIDE TETRAXETAN Other / unclassified 7400 mbq Intravenous

Indications

prostate carcinoma